Ardelyx, Inc.

Ardelyx, Inc. Earnings Recaps

ARDX Health Care 3 recaps
Next earnings: February 18, 2027 (estimated) · full calendar
Q3 2026 Nov 5, 2026

Ardelyx shares rose 8.6% after earnings, with investors responding to Q3 revenue growth of 19% year over year and progress on pipeline expansion. IBSRELA’s 23% growth led the quarter, while XPHOZAH grew 7%, a more modest pace.

Key takeaways
  • Total Q3 revenue from IBSRELA and XPHOZAH exceeded $125 million, up 19% year over year.
  • IBSRELA revenue was $96.3 million, up 23%; management said total prescriptions and market share continued to grow, while payer friction remains a focus.
  • XPHOZAH revenue was $29.2 million, up 7%; paid prescriptions grew 22% year over year, though management described the dialysis reimbursement environment as complex.
  • Ardelyx fully enrolled its ACCEL Phase III trial of IBSRELA in chronic idiopathic constipation ahead of schedule.
  • The company launched its first IBSRELA direct-to-consumer campaign in September and reported early increases in website traffic; it has not yet established the campaign’s effect on new patient starts.
Q2 2026 Aug 10, 2026

Ardelyx shares fell 18.5% after the company cut guidance in response to growing payer hurdles that slowed new patient starts for IBSRELA, signaling investor concerns over demand deceleration despite revenue growth.

Key takeaways
  • Combined revenue from IBSRELA and XPHOZAH reached $118 million, up 31% year-over-year and the highest quarterly total in company history.
  • New patient starts for IBSRELA were materially impacted by increased payer restrictions, dampening growth momentum.
  • Refill rates and total prescriptions hit record highs, supported by the IBSRELA Pharmacy Network and expanded sales force initiatives.
  • The company highlighted ongoing efforts to mitigate payer barriers, including doubling the field reimbursement team and ramping up direct-to-consumer marketing.
  • Management reaffirmed long-term revenue potential but will no longer pursue further legal action regarding CMS reimbursement, removing a potential lever for future pricing flexibility.
Q3 2025 Oct 31, 2025

Ardelyx demonstrated strong performance in Q3 2025, driven by robust growth in product revenues, particularly from IBSRELA, which saw a 92% year-over-year increase.

Key takeaways
  • Total product revenue reached $105.5 million, a 15% increase year-over-year.
  • IBSRELA generated $78.2 million, a record high, with an upward revision of revenue guidance to $270-$275 million for the year.
  • XPHOZAH contributed $27.4 million in revenue, reflecting a 9% increase from the previous quarter.
  • Introduction of ARDX-10531, a next-generation NHE3 inhibitor, marks a significant step in expanding the company’s pipeline.
  • Strong leadership addition with Sue Hohenleitner as CFO, enhancing financial and strategic insights.